Pacira Pharma (PCRX) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Pacira Pharmaceuticals Reports 2016 Financial Results and Provides Business Update
March 1, 2017 7:30 AM EST-- Phase 4 EXPAREL® study in total knee arthroplasty meets co-primary endpoints for pain control and opioid reduction against an active comparator ---- EXPAREL net product sales up 11% year-over-year ---- EXPAREL net product sales expected to be in the range of $290 to $310 million in 2017 ---- Conference call today at 8:30 a.m. ET --
PARSIPPANY, N.J., March 01, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals,... More
